| Citation: |
YANG Zhenhua, YE Liang, FANG Surong, GU Wei. Clinical Value of 99mTc-3PRGD2 Molecular Image in Evaluating Effect of Recombinant Endostatin[J]. Cancer Research on Prevention and Treatment, 2018, 45(5): 306-310. DOI: 10.3971/j.issn.1000-8578.2018.17.0596
|
To observe the clinical value of 99mTc-3PRGD2 molecular image in evaluating the effect of recombinant endostatin.
We enrolled 72 NSCLC patients, among which 36 patients in endostar plus chemotherapy group (observation group) and 36 patients in chemotherapy alone group (control group). Kaplan-Meier survival analysis curves were used to analyze the difference of progression-free survival(PFS) between two groups. The correlation of PFS with 99mTc-3PRGD2 SPECT/CT imaging T/N value difference before treatment and after four cycles of treatment with PFS was calculated by linear correlation.
The T/N value in control group before and after treatment were (6.89±2.03) and (6.76±2.01) (P=0.073), while those in observation group were (6.74±2.22) and (3.84±1.14) (P < 0.001). The difference of T/N value before and after treatment was significantly different between observation group and control group ((2.906±1.86) vs. (0.131±0.42), P < 0.001) and the change of T/N value in observation group was closely related to PFS (r=0.879, P < 0.001). Kaplan-Meier survival analysis by Log rank test showed mPFS in observation group and control group were (7.417±0.42) months and (6.194±0.26) months (P=0.003).
The 99mTc-3PRGD2 molecular imaging T/N value significantly changes before and after treatment in observation group and the change of T/N value is closely related to PFS, which suggest 99mTc-3PRGD2 molecular imaging has clinical value in the assessment of recombinant endostatin efficacy in future.
| [1] |
Zhou Y, Kim YS, Chakraborty S, et al. 99mTc-labeled cyclic RGD peptides for noninvasive monitoring of tumor integrin αVβ3 expression[J]. Mol Imaging, 2011, 10(5): 386-97. http://www.ncbi.nlm.nih.gov/pubmed/21521559
|
| [2] |
Wang L, Shi J, Kim YS, et al. Improving tumor-targeting capability and pharmacokinetics of (99m)Tc-labeled cyclic RGD dimers with PEG(4) linkers[J]. Mol Pharm, 2009, 6(1): 231-45. doi: 10.1021/mp800150r
|
| [3] |
Shao G, Gu W, Guo M, et al. Clinical study of 99mTc-3P-RGD2 peptide imaging in osteolytic bone metastasis[J]. Oncotarget, 2017, 8(43): 75587-96. https://www.researchgate.net/publication/273637512_Study_of_Bone_Surface_Absorbed_Dose_in_Treatment_of_Bone_Metastases_via_Selected_Radiopharmaceuticals_Using_MCNP4C_Code_and_Available_Experimental_Data
|
| [4] |
Khawar IA, Kim JH, Kuh HJ, et al. Improving drug delivery to solid tumors: priming the tumor microenvironment[J]. J Control Release, 2015, 201: 78-89. doi: 10.1016/j.jconrel.2014.12.018
|
| [5] |
Tan Q, Saggar JK, Yu M, et al. Mechanisms of drug resistance related to the microenvironment of solid tumors and possible strategies to inhibit them[J]. Cancer J, 2015, 21(4): 254-62. doi: 10.1097/PPO.0000000000000131
|
| [6] |
Jayson GC, Kerbel R, Ellis LM, et al. Antiangiogenic therapy in oncology: current status and future directions[J]. Lancet, 2016, 388(100043): 518-29. http://europepmc.org/abstract/MED/26853587
|
| [7] |
Zhang ZY, Chen LL, Xu W, et al. Effects of silencing endothelin-1 on invasion and vascular formation in lung cancer[J]. Oncol Lett, 2017, 13(6): 4390-6. doi: 10.3892/ol.2017.6027
|
| [8] |
Han B, Xiu Q, Wang H, et al. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer[J]. J Thorac Oncol, 2011, 6 (6) :1104-9. doi: 10.1097/JTO.0b013e3182166b6b
|
| [9] |
Bao Y, Peng F, Zhou QC, et al. Phase Ⅱ trial of recombinant human endostatin in combination with concurrent chemoradiotherapy in patients with stage Ⅲ non-small-cell lung cancer[J]. Radiother Oncol, 2015, 114(2): 161-6. doi: 10.1016/j.radonc.2014.11.039
|
| [10] |
Zhang FL, Gao EY, Shu RB, et al. Human Recombinant Endostatin Combined with Cisplatin Based Doublets in Treating Patients with Advanced NSCLC and Evaluation by CT Perfusion Imaging[J]. Asian Pac J Cancer Prev, 2015, 16(15): 6765-8. doi: 10.7314/APJCP.2015.16.15.6765
|
| [11] |
Yan F, Xu X, Chen Y, et al. A Lipopeptide-Based alphavbeta(3) Integrin-Targeted Ultrasound Contrast Agent for Molecular Imaging of Tumor Angiogenesis[J]. Ultrasound Med Biol, 2015, 41(10): 2765-73. doi: 10.1016/j.ultrasmedbio.2015.05.023
|
| [12] |
Zhang Z, Zhao X, Ding C, et al. (99m)Tc-3PRGD2 SPECT/CT imaging for monitoring early response of EGFR-TKIs therapy in patients with advanced-stage lung adenocarcinoma[J]. Cancer Biother Radiopharm, 2016, 31(7): 238-45. doi: 10.1089/cbr.2016.2052
|
| [13] |
Ma Q, Min K, Wang T, et al. (99m)Tc-3PRGD2 SPECT/CT predicts the outcome of advanced nonsquamous non-small cell lung cancer receiving chemoradiotherapy plus bevacizumab[J].Ann Nucl Med, 2015, 29(6): 519-27. doi: 10.1007/s12149-015-0975-5
|
| [14] |
Jin X, Liang N, Wang M, et al. Integrin imaging with 99mTc-3PRGD2 SPECT/CT shows high specificity in the diagnosis of lymph node metastasis from non-small cell lung cancer[J]. Radiology, 2016, 281(3): 958-66. doi: 10.1148/radiol.2016150813
|
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: